Enhancing anti-tumour efficacy with immunotherapy combinations
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
X Yang, L Ma, X Zhang, L Huang, J Wei - Experimental Hematology & …, 2022 - Springer
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal
hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately …
hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately …
CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome
S Arcangeli, C Bove, C Mezzanotte… - The Journal of …, 2022 - Am Soc Clin Investig
Chimeric antigen receptor (CAR) T cell expansion and persistence represent key factors to
achieve complete responses and prevent relapses. These features are typical of early …
achieve complete responses and prevent relapses. These features are typical of early …
Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies
B Greco, V Malacarne, F De Girardi, GM Scotti… - Science translational …, 2022 - science.org
Immunotherapy with chimeric antigen receptor (CAR)–engineered T cells showed
exceptional successes in patients with refractory B cell malignancies. However, first-in …
exceptional successes in patients with refractory B cell malignancies. However, first-in …
Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy
T Sauerer, GF Velázquez, C Schmid - Molecular Cancer, 2023 - Springer
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the expansion
of immature myeloid cells in the bone marrow (BM) and peripheral blood (PB) resulting in …
of immature myeloid cells in the bone marrow (BM) and peripheral blood (PB) resulting in …
CD123 as a therapeutic target in the treatment of hematological malignancies
U Testa, E Pelosi, G Castelli - Cancers, 2019 - mdpi.com
The interleukin-3 receptor alpha chain (IL-3Rα), more commonly referred to as CD123, is
widely overexpressed in various hematological malignancies, including acute myeloid …
widely overexpressed in various hematological malignancies, including acute myeloid …
Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients
S Arcangeli, L Falcone, B Camisa, F De Girardi… - Frontiers in …, 2020 - frontiersin.org
Chimeric antigen receptor (CAR) T cell expansion and persistence emerged as key efficacy
determinants in cancer patients. These features are typical of early-memory T cells, which …
determinants in cancer patients. These features are typical of early-memory T cells, which …
Immune landscape after allo-HSCT: TIGIT-and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse
V Gournay, N Vallet, V Peux, K Vera… - Blood, The Journal …, 2022 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective
treatment for selected patients with acute myeloid leukemia (AML) and relies on a “graft …
treatment for selected patients with acute myeloid leukemia (AML) and relies on a “graft …
TCR redirected T cells for cancer treatment: achievements, hurdles, and goals
F Manfredi, BC Cianciotti, A Potenza, E Tassi… - Frontiers in …, 2020 - frontiersin.org
Adoptive T cell therapy (ACT) is a rapidly evolving therapeutic approach designed to
harness T cell specificity and function to fight diseases. Based on the evidence that T …
harness T cell specificity and function to fight diseases. Based on the evidence that T …
Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans
FM Uhl, S Chen, D O'Sullivan… - Science translational …, 2020 - science.org
Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic cell transplantation
(allo-HCT) has a dismal prognosis. We found that T cells of patients relapsing with AML after …
(allo-HCT) has a dismal prognosis. We found that T cells of patients relapsing with AML after …